

# TENDYNE™

Transcatheter Mitral Valve Implantation

SUSTAINED MR ELIMINATION

## QUALITY TIME SECURED





Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

  
**Abbott**

TENDYNE™ TMVI:

# FIRST-IN-CLASS TRANSCATHETER MITRAL VALVE IMPLANTATION THERAPY


The Tendyne clinical program spans several years and includes more than 300 patients,<sup>1</sup> with more studies to come.



# PREDICTABLE AND SUSTAINABLE MR ELIMINATION AND SYMPTOM IMPROVEMENT


Tendyne TMVI is a breakthrough therapy that can eliminate mitral regurgitation at discharge and sustain it through 2 years. 100% of survivors had MR grade 1+ or less at 1 and 2 years, and 0% structural valve dysfunction was detected at 2 years.<sup>2</sup>

## CHANGE IN MITRAL REGURGITATION<sup>2</sup>



**93%**  
SUSTAINED MR  
ELIMINATION IN PATIENTS  
THROUGH 2 YEARS<sup>2</sup>

## SYMPTOM IMPROVEMENT<sup>2</sup> (NYHA FUNCTIONAL CLASS)




**82%**  
NYHA FUNCTIONAL  
CLASS I/II  
AT 2 YEARS<sup>2</sup>

# SECURE MORE QUALITY TIME FOR YOUR PATIENTS


Tendyne™ patients report clinically significant improvements in function and quality of life. The two-year mortality outcomes (39%) were clinically acceptable considering the advanced age and underlying comorbidities of the population.<sup>2</sup>

## 6-MINUTE WALK TEST<sup>3</sup>



**61.8%**  
IMPROVED BY  $\geq 24$  m  
AT 1 YEAR<sup>4</sup>

## QUALITY OF LIFE<sup>2</sup>




**>19 POINT**  
IMPROVEMENT FROM  
BASELINE<sup>2</sup>  
(paired comparison)

# CLINICALLY SIGNIFICANT REDUCTION IN HEART FAILURE HOSPITALIZATIONS

Assessed over a 6-month duration both before and after the procedure, heart failure hospitalizations were reduced by nearly 50% per patient-year.<sup>2</sup>

## HEART FAILURE HOSPITALIZATION RATE




NEARLY  
**50%**  
REDUCTION IN  
HEART FAILURE  
HOSPITALIZATION  
EVENTS PER  
PATIENT-YEAR\*<sup>2</sup>

\*in the 6 months pre- and post-procedure

## BACKED BY AN EXCELLENT SAFETY PROFILE

Tendyne demonstrated outstanding acute and 30-day outcomes in clinical study.

- Beating heart procedure—**no requirement for CPB** or rapid pacing
- Low major adverse events (CEC-adjudicated)<sup>4</sup>



\*Technical success per MVARC.

# WITH TENDYNE™ TMVI, YOU CAN IMPLANT WITH CONFIDENCE


Tendyne is designed with the unique challenges of the mitral anatomy in mind.

- Valve sealing and securement enabled by anchoring system
- Fully repositionable and retrievable intraprocedurally
- Controlled and predictable procedure

## TENDYNE TMVI PROCEDURE


1

A delivery system positions the Tendyne valve in the heart via an incision in the left side of the chest.




2

The valve is secured by applying tension to the tether, which is attached to an apical pad placed over the access site.



3

Once the Tendyne valve is optimally positioned within the mitral annulus, the delivery system is removed.




# REACH A BROAD RANGE OF PATIENTS WITH FLEXIBLE DESIGN AND SIZING

The distinct design enables safe and effective treatment for a broad range of patients.

- Low risk for paravalvular leak<sup>4</sup>
- Reduce risk of LVOT obstruction with 2 valve profiles
- Wide range of annular dimensions addressed with multiple frame sizes

## VALVE

Dual-frame design with ability to customize fit to individual patient anatomies




# REACH MORE MR PATIENTS WITH TENDYNE™ TMVI

- First-in-class breakthrough therapy
- Predictable and sustained MR elimination through 2 years<sup>2</sup>
- Significant improvement of heart failure symptoms<sup>2</sup>
- Excellent procedural safety<sup>2</sup>
- Enhanced quality of life<sup>2</sup>

*“Six months after the operation, I began working. I became a normal person again.”*

– Sribalan, Tendyne patient



**Elimination of MR is possible.  
Screen your patients for a new,  
minimally invasive mitral valve  
replacement therapy:**

**TENDYNE TMVI**

#### References:

1. Abbott data on file.
2. Muller D, et al. Two-Year Outcomes of Tendyne Transcatheter Mitral Valve Implantation to Treat Symptomatic, Severe Mitral Regurgitation. Presented at: PCR E-Course, June, 2020.
3. Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. *J Am Coll Cardiol*. 2019;73(11):1250-1260.
4. Expanded Clinical Study of Tendyne Mitral Valve System “CE Study” Clinical Study Report. Study Document No: CS-03 Ver. C.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [eifu.abbottvascular.com](http://eifu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott.

#### Abbott

Park Lane, Culliganlaan 2b, 1831 Diegem, Belgium, Tel: +32 2 714 14 11  
[www.cardiovascular.abbott](http://www.cardiovascular.abbott)

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.

© 2020 Abbott. All rights reserved. MAT-1901569 v2.0 | Item approved for OUS use only.

